Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON40686
NL-OMON40686
Completed
Not Applicable

Assessment of Bone Material Strength by Microindentation in vivo in Patients with Acromegaly - BMS in Acromegaly

Endocrinologie0 sites70 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsbone mechanical propertiesvertebral fracture1002111210017322

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
bone mechanical properties
Sponsor
Endocrinologie
Enrollment
70
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Endocrinologie

Eligibility Criteria

Inclusion Criteria

  • •patients with Acromegaly and
  • •Age above 18 years
  • •Available data on acromegalic disease, tumor characteristics
  • •Stable hormone situation for 3 months

Exclusion Criteria

  • •Active infection of the measurement site.
  • •Recent fracture of the tibia.
  • •Underlying metabolic bone disease, including vitamin D deficiency.
  • •Untreated hypogonadism

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Assessment of Bone Material Strength by Microindentation in vivo after Fracture or Surgery-related Immobilizatio
NL-OMON43556eids Universitair Medisch Centrum42
Active, not recruiting
Phase 1
A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 12 Month, Multicenter, Double-blind, Randomized, Parallel Group Study Comparing Weekly Oral Risedronate 35 mg and PlaceboOsteoporosis is a systemic skeletal disorder characterized by low bone mass and micro-architectural deterioration of bone tissue leading to enhanced bone fragility and susceptibility to fracture. Postmenopausal women with a diagnosis of osteopenia (T score between –2.5 and –1.0 based on the World Health Organization classification) may also be at risk of fracture.MedDRA version: 7.0 Level: PT Classification code 10031285
EUCTR2005-003033-41-GBProcter & Gamble Technical Centres Limited156
Active, not recruiting
Not Applicable
A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 12 Month, Multicenter, Double-blind, Randomized, Parallel Group Study Comparing Weekly Oral Risedronate 35 mg and Placebo
EUCTR2005-003033-41-DEProcter & Gamble Technical Centres Limited156
Completed
Phase 4
Prospective evaluation of bone strength, physical activity, falls, subsequent fractures and mortality in patients presenting with a recent clinical fracture.loss of bone mass1001329610017322
NL-OMON41637Viecuri Medisch Centrum voor Noord-Limburg500
Recruiting
Not Applicable
Evaluation of bone mineral density and bone metabolism during treatment with the januskinaseinhibitor upadacitinib in patients with rheumatoid arthritis
DRKS00021182Campus Kerckhoff der Jusuts-Liebig-Universität Gießen, Abteilung für Rheumatologie, Immunologie, Osteologie und Physikalische Medizin60